iStock_000004063879Small2

Let us help you by informing patients about your pancreatic cancer clinical trials.  If you are conducting clinical trials, we want to know about your studies!

14
nov
2013
Volunteer Recruitment

Our volunteers are second to none.  Passionate, focused and relentless in their desire to change the course of history for pancreatic cancer.  Are you ready to get involved?

Kimmel-PanCan_095_2

For every $1 invested by Pancreatic Cancer Action Network between 2003-2011, our research grant recipients have gone on to receive $9.93 in subsequent funding to support their pancreatic cancer studies.

Every grant recipient during that time has authored an average of 13 pancreatic cancer-related papers published in biomedical journals, and every paper has been read, built upon, and cited by other scientists an average of nearly eight times in other articles.

recalcitrant-cancer-research

Morbi erat ipsum, mollis nec convallis vitae, malesuada rhoncus lorem. Cras dignissim nulla eget nunc commodo gravida. Vestibulum sapien nisl, ornare auctor, consectetuer quis, posuere tristique, odio. Fusce ultrices ullamcorper odio. Ut augue nulla, interdum at, adipiscing non, tristique eget, neque. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Ut pede est, condimentum id, scelerisque ac, malesuada non, quam. Proin eu ligula ac sapien suscipit blandit. Suspendisse euismod. Read More »

Capitol building Washington

DECEMBER 21, 2012

FOR IMMEDIATE RELEASE

THE RECALCITRANT CANCER RESEARCH ACT, FORMERLY KNOWN AS THE PANCREATIC CANCER RESEARCH & EDUCATION ACT, Passes Congress

The Pancreatic Cancer Action Network Urges President Obama to Sign the Legislation into Law

Manhattan Beach, CA (December 21, 2012) — The Recalcitrant Cancer Research Act, formerly known as the Pancreatic Cancer Research & Education Act, has passed Congress today as part of the National Defense Authorization Act and will now be sent to President Obama to sign into law. The legislation requires the National Cancer Institute (NCI) to evaluate its current efforts in studying pancreatic cancer, lung cancer, and other recalcitrant cancers, and focus on ways to improve outcomes.

Read More »

newsimg2

November 9, 2012

FOR IMMEDIATE RELEASE

STUDY SHOWS ABRAXANE® EXTENDS SURVIVAL FOR PATIENTS WITH ADVANCED PANCREATIC CANCER

MANHATTAN BEACH, CA (November 9, 2012) — The Pancreatic Cancer Action Network is pleased to announce Abraxane® extends survival for patients with advanced pancreatic cancer. According to Celgene Corporation, Abraxane in combination with gemcitabine when given to advanced pancreatic cancer patients who had not received previous treatment demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone. Read More »

newsimg1

November 1, 2012

FOR IMMEDIATE RELEASE

The Pancreatic Cancer Action Network Calls on the Public to Take Action During National Pancreatic Cancer Awareness Month in November

Manhattan Beach, CA (November 1, 2012) — Over the past 30 years there has been a revolution in science and medicine, resulting in increased survival rates for many diseases such as AIDS, breast cancer and diabetes. Unfortunately, pancreatic cancer has not benefited from these medical advances because historically there haven’t been enough people who know it. Not enough people fighting for action and not enough research to end it. As a result, pancreatic cancer is the only one of the top cancer killers with a five-year survival rate in the single digits, at just six percent. But the Pancreatic Cancer Action Network has a vision to change that. Read More »